• iBio received Australian regulatory clearance to start a first-in-human Phase 1 trial of IBIO-600 in overweight and obese adults in fiscal Q3 2026.
• Study will assess safety and how drug behaves in body, with initial dosing expected in calendar Q2 2026.
• New preclinical findings for IBIO-610 were already presented, supporting its potential to improve body composition in obesity without detailing technical measurements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-059408), on May 12, 2026, and is solely responsible for the information contained therein.